Remove 2026 Remove Leads Remove Networking
article thumbnail

Sandoz mobilises critical medicine production in Europe

European Pharmaceutical Review

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.

article thumbnail

Sandoz plans new biologics production plant construction in Slovenia

Pharmaceutical Technology

It represents one of the largest-ever global private-sector investments in the country and strengthens the company’s Europe-wide production network. At Sandoz, we are determined to continue leading the way in driving access to these critical medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes.

article thumbnail

New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation

pharmaphorum

Angelini Ventures will lend its network and knowledge of the life sciences industry to “strengthen the bridge between the excellence of Italian academic research and the development of drug discovery programmes in order to identify new treatment options,” said Angelini Industries CEO Professor Sergio Marullo di Condojanni in a statement. “We

article thumbnail

The post-Covid New Normal: a golden opportunity for the NHS?

pharmaphorum

Within those, two things are critical for him: helping NICE become the “world class benchmark agency for HTA”, and a focus on ‘disease missions’ that bring together digital technology with the NHS’s network. Reducing complexity across the NHS.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. The resulting reduced profit margins could lead to further supply chain constraints of some loss-making products in certain markets. The entire pharma industry will be affected by the fallout.

Pharma 64
article thumbnail

The key to succeeding at population health analytics

Clarify Health

billion by 2026. Learn why Clarify was lauded by Frost & Sullivan for having the leading population health management (PHM) analytics solution and with comprehensive precise SDoH insights. Reports estimate that the healthcare analytics market size is expected to grow to $75.1